Brownlee Noel A, Perkins L Allen, Stewart Will, Jackle Beth, Pettenati Mark J, Koty Patrick P, Iskandar Samy S, Garvin A Julian
Department of Pathology, Wake Forest University School of Medicine, Winston-Salem, NC, USA.
Arch Pathol Lab Med. 2007 Mar;131(3):446-51. doi: 10.5858/2007-131-446-RTADQI.
Clear cell sarcoma of the kidney (CCSK) is a prognostically unfavorable renal neoplasm of childhood. Previous cytogenetic studies of CCSK have reported balanced translocations t(10;17)(q22;p13) and t(10;17)(q11;p12). Although the tumor suppressor gene p53 is located at the chromosome 17p13 breakpoint, p53 abnormalities are rarely present in these tumors.
To identify cytogenetic abnormalities in CCSK and correlate these findings with other clinicopathologic parameters.
A retrospective review of CCSK patients from 1990 to 2005 was conducted at our medical center. We performed clinical and histologic review, p53 immunohistochemical and classic cytogenetics (or ploidy analysis), and p53 fluorescence in situ hybridization analyses.
Five male patients (age range, 6 months to 4 years) were identified with cytogenetic abnormalities. Of 3 cytogenetically informative cases, one revealed a clonal balanced translocation t(10;17)(q22;p13) and an interstitial deletion of chromosome 14, del(14)(q24.1q31.1), and the other 2 patients had normal karyotypes. Fluorescence in situ hybridization for p53 in the t(10;17) case revealed no deletion. Immunohistochemical evaluation of p53 demonstrated lack of nuclear protein accumulation in all cases.
Together with the published literature, our results indicate that translocation (10;17) and interstitial deletions of chromosome 14q are recurring cytogenetic lesions in CCSK. To date, 3 cases of CCSK or "sarcomatoid Wilms tumors" have been reported to exhibit t(10;17). One previously reported case of CCSK contained deletion 14q. Results of p53 immunohistochemistry and/or p53 fluorescence in situ hybridization in this report suggest lack of mutations or deletions of this tumor suppressor in these CCSK cases. The t(10;17) breakpoint and deletion of chromosome 14q24 suggest that other genes are involved in tumor pathogenesis.
肾透明细胞肉瘤(CCSK)是一种儿童期预后不良的肾脏肿瘤。既往对CCSK的细胞遗传学研究报告了平衡易位t(10;17)(q22;p13)和t(10;17)(q11;p12)。尽管肿瘤抑制基因p53位于染色体17p13断点处,但这些肿瘤中很少出现p53异常。
确定CCSK中的细胞遗传学异常,并将这些发现与其他临床病理参数相关联。
在我们的医学中心对1990年至2005年的CCSK患者进行回顾性研究。我们进行了临床和组织学检查、p53免疫组织化学和经典细胞遗传学(或倍体分析)以及p53荧光原位杂交分析。
确定了5例有细胞遗传学异常的男性患者(年龄范围为6个月至4岁)。在3例细胞遗传学信息明确的病例中,1例显示克隆性平衡易位t(10;17)(q22;p13)和染色体14的间质性缺失,del(14)(q24.1q31.1),另外2例患者核型正常。t(10;17)病例中p53的荧光原位杂交显示无缺失。p53的免疫组织化学评估显示所有病例均缺乏核蛋白积累。
与已发表的文献一起,我们的结果表明,易位(10;17)和染色体14q的间质性缺失是CCSK中反复出现的细胞遗传学病变。迄今为止,已有3例CCSK或“肉瘤样威尔姆斯瘤”被报道表现出t(10;17)。之前报道的1例CCSK病例包含14q缺失。本报告中p53免疫组织化学和/或p53荧光原位杂交的结果表明,这些CCSK病例中该肿瘤抑制基因缺乏突变或缺失。t(10;17)断点和染色体14q24缺失表明其他基因参与了肿瘤发病机制。